Actively Recruiting
CD70-targeted PET/CT Imaging for Diagnosing Malignant Cancers
Led by RenJi Hospital · Updated on 2026-05-12
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of CD70-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging to diagnose several types of malignant cancers, including renal cell carcinoma (especially clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC). This phase 2 study aims to assess how well these imaging tracers work compared to conventional imaging methods and how they might influence clinical decisions. The trial is sponsored by RenJi Hospital and focuses on both confirmed and suspected cases of these cancers. Participants will receive an injection of one of several radioactive tracers targeting CD70, including [18F]F-RESCA-RCCB6, [18F]F-RESCA-R8B4, [68Ga]Ga-NOTA-R8B4, [18F]F-RESCA-RD06, or [68Ga]Ga-NOTA-RD06. After injection, patients will undergo whole-body immunoPET/CT scans 1 to 2 hours later to capture images of tumors and normal tissues. The uptake of these tracers will be measured visually and quantitatively to evaluate diagnostic accuracy. Patients may also be followed for routine surveillance and to evaluate treatment response after the initial imaging. During the study, researchers will analyze the patterns of tracer uptake in tumors and compare them to conventional imaging results. They will use measures like sensitivity, specificity, positive and negative predictive values, and accuracy to assess the imaging's diagnostic value. The impact of the imaging on clinical decision-making will also be evaluated over 3 to 6 months after tracer injection. Participants will be monitored for safety throughout the process, with the total study duration depending on follow-up assessments.
CONDITIONS
Brief Title
CD70-targeted immunoPET Imaging of Malignant Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 80 years and of any sex
- Histologically confirmed diagnosis or suspected renal cancer (especially clear cell renal cell carcinoma), lymphoma, or nasopharyngeal carcinoma
- Able to give signed informed consent and comply with study requirements
You will not qualify if you...
- Pregnant
- Severe liver or kidney failure
- Allergy to single-domain antibody radiopharmaceuticals
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants receive an injection of a CD70-targeted tracer followed by whole-body immunoPET/CT imaging 1-2 hours after tracer injection to assess tumor uptake and normal organ distribution.
1 visit (in-person)
Duration - 3 to 6 months
Participants are monitored for up to 6 months to evaluate tracer uptake patterns, diagnostic value, and the impact of imaging on clinical decision-making.
Follow-up visits as needed over 3 to 6 months
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, China, 200127
Actively Recruiting
Research Team
W
Weijun Wei, Ph.D. & M.D.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here